The efocus is faster absorption [Power / Sample Size]

posted by alejandro_jo1990 – Spain, 2022-09-02 20:57 (540 d 19:01 ago) – Posting: # 23263
Views: 2,029

❝ I am wondering why PK superiority? I am not getting if you do not prove faster onset of action with PD superiority, you can have advantage. Already the discussion for Tmax assessment (EMA PSG) is discussed in forum. Could you provide more details for not focusing on PD superiority?


Hi Diven thanks for the answer!
If you have the link to the thread reagarding the Tmax discussion, could you paste it here please? Regarding the issue, the want to demonstrate faster absorption not faster onset of action, therefore the whole discussion about if AUC, therapeutic ranges etc
BR
Alex

Complete thread:

UA Flag
Activity
 Admin contact
22,911 posts in 4,806 threads, 1,636 registered users;
28 visitors (0 registered, 28 guests [including 6 identified bots]).
Forum time: 14:59 CET (Europe/Vienna)

The history of statistics is like a telephone directory:
the plot is boring, full of numbers and the cast is endless.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5